Скачать или смотреть Topline results from the SURPASS-ET trial: ropeginterferon alfa-2b versus anagrelide in ET

Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the topline results of the Phase III SURPASS-ET (NCT04285086) trial, highlighting the superiority of ropeginterferon alfa-2b over anagrelide in controlling disease parameters in patients with essential thrombocythemia (ET) who have relapsed following frontline treatment with hydroxyurea. Dr Masarova notes that ropeginterferon alfa-2b demonstrated a significant advantage over anagrelide in all primary and secondary endpoints, including a doubling of the rate of complete hematologic remission. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.